ImmunoCellular Therapeutics (IMUC) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
March 9, 2015 4:01 PM EDTLOS ANGELES, March 9, 2015 /PRNewswire/ --Â ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the fourth quarter and year ended December 31, 2014.Â
"We continued to make progress in 2014 toward building ImmunoCellular into a leading cancer immunotherapy company, including key accomplishments in all aspects of our business: advancing our dendritic cell-based vaccine pipeline; working with regulatory bodies in the United States and Europe to design a high quality phase III registration trial for ICT-107; achieving phase III operational readiness and commercial-grade manufacturing; strategically... More
